TriSalus Life Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $205.79M
- P/E (TTM)
- –
- Dividend yield
- –
About TriSalus Life Sciences
Surgical & Medical Instruments & Apparatus, SIC 3841
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops drug delivery systems and investigational therapeutics for treating solid tumors. Its primary commercial product is the TriNav Infusion System, which utilizes Pressure-Enabled Drug Delivery technology and SmartValve mechanisms to overcome high intratumoral pressure during interventional embolization procedures. The business operates across delivery device technology and investigational immunotherapy segments, including development of nelitolimod and the Pancreatic Retrograde Venous Infusion system. Its direct customers comprise hospital value analysis committees, interventional radiologists, medical oncologists, and related clinical support personnel.
The enterprise markets its proprietary devices across the United States through a dedicated commercial network of 43 sales and marketing professionals. Its delivery technology has been deployed in more than 31,000 clinical procedures across multiple participating hospitals, ambulatory surgery centers, and academic medical institutions. TriSalus Life Sciences is incorporated under the laws of Delaware, with the provided report text containing no specific details regarding its corporate headquarters.
Summary of the business section of TriSalus Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TriSalus Life Sciences, Inc.
- Headquarters
- Westminster, CO
- Address
- 6272 West 91st Avenue 80031
- Phone
- (415) 336-8917
- Employees
- 102, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Grant Thornton LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- TLSI
- Other tickers
- TLSIW
- Exchange
- Nasdaq
- IPO date
- Dec 21, 2020
- Shares outstanding
- 62M, Aug 4, 2026
- Public float
- $111.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1826667
- CUSIP
- 89680M101
- ISIN
- US89680M1018
- EIN
- 85-3009869
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mary T. Szela | CEO and President, Director | 1,077,683 |
| David Patience | Chief Financial Officer | 261,107 |
| Richard Marshak | Chief Commercial Officer | 128,319 |
| Richard Henry Marshall | Chief Medical Officer | 30,000 |
| Bryan F. Cox | Chief of Research | 163,415 |
| Jodi Devlin | Chief of Clinical Operations | 97,364 |
| Jennifer Stevens | Chief Regulatory Officer | 124,110 |
| James Emmett Young | Chief Financial Officer | 79,663 |
| Michael P. Stansky | Director | 1,640,420 |
| Mats Wahlstrom | Director | 2,962,030 |
| Gary B. Gordon | Director | 72,510 |
| William Valle | Director | 83,241 |
| Kerry R. Hicks | Director | 2,317,400 |
| David J. Matlin | Director | 7,550,145 |
| Sean Murphy | Director | 679,256 |
| Arjun JJ Desai | Director | 247,127 |
| Liselotte Hyveled | Director | 10,040 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mary Szela | $4.82M | $6.89M | $2.50M | $83 | – |
| FY2024 Mary Szela | $4.14M | $1.52M | $1.85M | $59 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 102 full-time employees,”
Corporate history
Events identified from SEC filings